| VRSK |
Report |
Adjusted EPS |
BEAT |
pred ~$1.99 vs. cons $1.94 |
HIGH |
| VRSK |
Report |
Revenue |
IN-LINE |
pred ~$805M vs. cons $802M |
MEDIUM |
| VRSK |
Report |
Organic constant-currency (OCC) revenue growth (subscriptions ~7%) |
IN-LINE |
pred ~5.0% OCC vs. cons ~5.0% |
MEDIUM |
| VRSK |
Guide |
FY2026 revenue guidance |
UNCHANGED |
guide ~$3.19-3.24B (mid $3.215B) vs. cons ~$3.22B (FY2026) |
MEDIUM |
| VRSK |
Guide |
FY2026 adjusted EPS guidance |
UNCHANGED |
guide ~$7.45-7.75 (mid $7.60) vs. cons ~$7.62 (FY2026) |
MEDIUM |
| VRSK |
Guide |
FY2026 adj. EBITDA margin guidance |
UNCHANGED |
guide ~56.0-56.5% vs. cons ~56.3% (FY2026) |
MEDIUM |
| VRSK |
Guide |
H2 OCC reacceleration / subscription durability commentary |
UNKNOWN |
pred H2 OCC ramp toward ~6-7% vs. cons implied ~6.5% (2H2026) |
LOW |
| VRSK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| VRSK |
Return |
5-day cumulative residual |
-4.5% (FADE) |
Stock ran ~26% in a month (~15% in two weeks) to ~$212 at ~28x forward into the print, so a modest EPS beat + revenue in-line + reaffirm-only guide is a classic sell-the-news setup. With Q2 OCC still below the long-term algorithm and the FY guide requiring a ~$811M/qtr H2 hockey stick, reaffirm-not-raise implies the out-period math pulls estimates down even after the headline beat; margin optically dips on the ~120bps non-recurring year-ago FX comp. Expect the initial fade to extend as revisions drift lower and the AI-monetization story lacks fresh sizing. |
MEDIUM |